

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6600)

Date of Board Meeting

The board of directors (the “**Board**”) of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Thursday, March 24, 2022 for the purpose of, among other matters, considering and approving the final results of the Group for the year ended December 31, 2021 and recommendation of a final dividend, if any.

By Order of the Board

SciClone Pharmaceuticals (Holdings) Limited

Pan Rongrong

Chief Financial Officer and

Joint Company Secretary

Hong Kong, March 1, 2022

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

** For identification purpose only*